TrialBritish journal of haematology2018

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Luca Arcaini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.